Long-term survival after radiotherapy alone: radiation therapy oncology group prostate cancer trials.

[1]  M. Roach.  Is race an independent prognostic factor for survival from prostate cancer? , 1998, Journal of the National Medical Association.

[2]  A. Pollack,et al.  External beam radiotherapy dose response of prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[3]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[4]  D. Grignon,et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Grignon,et al.  1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531 , 1997 .

[6]  M. Roach,et al.  2107 An analysis of pretreatment characteristics and the risk of PSA failure by race and ethnicity in prostate cancer patients treated with definitive radiotherapy , 1997 .

[7]  A. Hanlon,et al.  115 Dose escalation with 3-D CRT in prostate cancer: Five year dose responses and optimal treatment , 1997 .

[8]  G E Hanks,et al.  Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Roach,et al.  Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. , 1996, The Journal of urology.

[10]  T E Schultheiss,et al.  Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. , 1996, International journal of radiation oncology, biology, physics.

[11]  A. Zietman,et al.  Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. , 1996, Urology.

[12]  D. Fryback,et al.  Long-term survival among men with conservatively treated localized prostate cancer. , 1995, JAMA.

[13]  J. Hugosson,et al.  Long-term survival and mortality in prostate cancer treated with noncurative intent. , 1995, The Journal of urology.

[14]  J. Hugosson,et al.  Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. , 1995, The Journal of urology.

[15]  R. Abrams,et al.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. , 1995, Urology.

[16]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[17]  P. Scardino,et al.  The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer , 1994, Cancer.

[18]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[19]  M. Barry,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.

[20]  L. Holmberg,et al.  High 10-year survival rate in patients with early, untreated prostatic cancer. , 1992, JAMA.

[21]  R. Cox,et al.  Status of radiation treatment of prostate cancer at Stanford University. , 1989, NCI monographs : a publication of the National Cancer Institute.

[22]  W. Sause,et al.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. , 1988, International journal of radiation oncology, biology, physics.

[23]  M. Roach,et al.  Formula to estimate risk of pelvic lymph node metastasis from the total Gleason score for prostate cancer. , 1988, The Journal of urology.

[24]  Gleason Df.  Histologic grade, clinical stage, and patient age in prostate cancer. , 1988 .

[25]  W. Sause,et al.  Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06. , 1987, International journal of radiation oncology, biology, physics.

[26]  D. Paulson,et al.  Prognosis of patients with stage D1 prostatic adenocarcinoma. , 1981, The Journal of urology.

[27]  D P Byar,et al.  Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies , 1972 .